請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/100559完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 簡穎秀 | zh_TW |
| dc.contributor.advisor | Yin-Hsiu Chien | en |
| dc.contributor.author | 葉千華 | zh_TW |
| dc.contributor.author | Chien-Hua Yeh | en |
| dc.date.accessioned | 2025-10-07T16:05:32Z | - |
| dc.date.available | 2025-07-30 | - |
| dc.date.copyright | 2025-10-07 | - |
| dc.date.issued | 2025 | - |
| dc.date.submitted | 2025-07-31 | - |
| dc.identifier.citation | [1]“Evaluation of the parents’ anxiety levels before and after the diagnosis of their child with a rare genetic disease: the necessity of psychological support - PubMed.” Accessed: Jul. 06, 2025. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/34583726/
[2]B. Martín López-Pardo et al., “Transforming NICU care: rapid WES and transcriptomics—validation, social impact, and cost analysis,” Eur. J. Pediatr., vol. 184, no. 7, p. 453, 2025, doi: 10.1007/s00431-025-06225-2. [3]H. S. Smith et al., “Key drivers of family-level utility of pediatric genomic sequencing: a qualitative analysis to support preference research,” Eur. J. Hum. Genet., vol. 31, no. 4, pp. 445–452, Apr. 2023, doi: 10.1038/s41431-022-01245-0. [4]中央健康保險署, “健保5月1日起給付癌症精準醫療「實體癌/血癌次世代基因定序檢測(NGS)」2萬多名癌友受惠,” 中央健康保險署. Accessed: Jul. 27, 2025. [Online]. Available: https://www.mohw.gov.tw/cp-16-78416-1.html [5]M. H. Wojcik et al., “Discordant results between conventional newborn screening and genomic sequencing in the BabySeq Project,” Genet. Med., vol. 23, no. 7, pp. 1372–1375, Jul. 2021, doi: 10.1038/s41436-021-01146-5. [6]L. G. Biesecker and R. C. Green, “Diagnostic clinical genome and exome sequencing,” N. Engl. J. Med., vol. 370, no. 25, pp. 2418–2425, Jun. 2014, doi: 10.1056/NEJMra1312543. [7]O. Ceyhan-Birsoy et al., “Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns: Results from the BabySeq Project,” Am. J. Hum. Genet., vol. 104, no. 1, pp. 76–93, Jan. 2019, doi: 10.1016/j.ajhg.2018.11.016. [8]S. Pereira et al., “Perceived Benefits, Risks, and Utility of Newborn Genomic Sequencing in the BabySeq Project,” Pediatrics, vol. 143, no. Suppl 1, pp. S6–S13, Jan. 2019, doi: 10.1542/peds.2018-1099C. [9]Z. Stark and R. H. Scott, “Genomic newborn screening for rare diseases,” Nat. Rev. Genet., vol. 24, no. 11, pp. 755–766, Nov. 2023, doi: 10.1038/s41576-023-00621-w. [10]H. Wang and R. Chen, “Chapter 3 - Whole-exome sequencing and whole-genome sequencing,” in Genetics and Genomics of Eye Disease, X. R. Gao, Ed., Academic Press, 2020, pp. 27–39. doi: 10.1016/B978-0-12-816222-4.00003-4. [11]D. Pushkarev, N. F. Neff, and S. R. Quake, “Single-molecule sequencing of an individual human genome,” Nat. Biotechnol., vol. 27, no. 9, pp. 847–850, Sep. 2009, doi: 10.1038/nbt.1561. [12]J. S. Berg et al., “Newborn Sequencing in Genomic Medicine and Public Health,” Pediatrics, vol. 139, no. 2, p. e20162252, Feb. 2017, doi: 10.1542/peds.2016-2252. [13]M.-T. Yan et al., “Allele-specific RT-PCR for the rapid detection of recurrent SLC12A3 mutations for Gitelman syndrome,” Npj Genomic Med., vol. 6, no. 1, pp. 1–8, Aug. 2021, doi: 10.1038/s41525-021-00230-8. [14]M. Arya, Shergill ,Iqbal S, Williamson ,Magali, Gommersall ,Lyndon, Arya ,Neehar, and H. R. and Patel, “Basic principles of real-time quantitative PCR,” Expert Rev. Mol. Diagn., vol. 5, no. 2, pp. 209–219, Mar. 2005, doi: 10.1586/14737159.5.2.209. [15]D. S. Kariyawasam et al., “Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study,” Lancet Child Adolesc. Health, vol. 7, no. 3, pp. 159–170, Mar. 2023, doi: 10.1016/S2352-4642(22)00342-X. [16]J. L. Taylor et al., “Newborn Blood Spot Screening Test Using Multiplexed Real-Time PCR to Simultaneously Screen for Spinal Muscular Atrophy and Severe Combined Immunodeficiency,” Clin. Chem., vol. 61, no. 2, pp. 412–419, Feb. 2015, doi: 10.1373/clinchem.2014.231019. [17]T. Kimizu et al., “Multiplex Real-Time PCR-Based Newborn Screening for Severe Primary Immunodeficiency and Spinal Muscular Atrophy in Osaka, Japan: Our Results after 3 Years,” Genes, vol. 15, no. 3, p. 314, Feb. 2024, doi: 10.3390/genes15030314. [18]S. E. McCandless and E. J. Wright, “Mandatory newborn screening in the United States: History, current status, and existential challenges,” Birth Defects Res., vol. 112, no. 4, pp. 350–366, Mar. 2020, doi: 10.1002/bdr2.1653. [19]M. S. Watson, M. A. Lloyd-Puryear, and R. R. Howell, “The Progress and Future of US Newborn Screening,” Int. J. Neonatal Screen., vol. 8, no. 3, p. 41, Jul. 2022, doi: 10.3390/ijns8030041. [20]K. Hohenfellner, E. Elenberg, G. Ariceta, G. Nesterova, N. A. Soliman, and R. Topaloglu, “Newborn Screening: Review of its Impact for Cystinosis,” Cells, vol. 11, no. 7, p. 1109, Mar. 2022, doi: 10.3390/cells11071109. [21]B. L. Therrell et al., “Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023),” Int. J. Neonatal Screen., vol. 10, no. 2, p. 38, May 2024, doi: 10.3390/ijns10020038. [22]R. Faden, A. J. Chwalow, N. A. Holtzman, and S. D. Horn, “A survey to evaluate parental consent as public policy for neonatal screening,” Am. J. Public Health, vol. 72, no. 12, pp. 1347–1352, Dec. 1982, doi: 10.2105/ajph.72.12.1347. [23]I. Matsuda, “Bioethical considerations in neonatal screening: Japanese experiences,” Southeast Asian J. Trop. Med. Public Health, vol. 34 Suppl 3, pp. 46–48, 2003. [24]K. Appelberg, L. Sörensen, R. H. Zetterström, M. Henriksson, A. Wedell, and L.-Å. Levin, “Cost-Effectiveness of Newborn Screening for Phenylketonuria and Congenital Hypothyroidism,” J. Pediatr., vol. 256, pp. 38-43.e3, May 2023, doi: 10.1016/j.jpeds.2022.10.046. [25]“Impact of Meeting Early Hearing Detection and Intervention Benchmarks on Spoken Language - PubMed.” Accessed: Jun. 08, 2025. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/36072546/ [26]Y.-H. Chien and W.-L. Hwu, “The modern face of newborn screening,” Pediatr. Neonatol., vol. 64, pp. S22–S29, Feb. 2023, doi: 10.1016/j.pedneo.2022.11.001. [27]B. A. Tarini and A. J. Goldenberg, “Ethical Issues with Newborn Screening in the Genomics Era,” Annu. Rev. Genomics Hum. Genet., vol. 13, pp. 381–393, 2012, doi: 10.1146/annurev-genom-090711-163741. [28]“Genetic conditions often lead to insurance refusal | Reuters.” Accessed: Jun. 08, 2025. [Online]. Available: https://www.reuters.com/article/business/healthcare-pharmaceuticals/genetic-conditions-often-lead-to-insurance-refusal-idUSCOL575585/?utm_source=chatgpt.com [29]A. Messenger, “Some say it’s ‘genetic discrimination’, but insurance companies are fighting for access to these test results,” The Guardian, May 14, 2024. Accessed: Jun. 08, 2025. [Online]. Available: https://www.theguardian.com/australia-news/article/2024/may/12/life-insurance-industry-customers-genetic-tests-ban [30]T. Yanes et al., “Future implications of polygenic risk scores for life insurance underwriting,” Npj Genomic Med., vol. 9, no. 1, pp. 1–6, Mar. 2024, doi: 10.1038/s41525-024-00407-x. [31]G. Shen, W. Li, Y. Zhang, and L. Chen, “Next-generation sequencing based newborn screening and comparative analysis with MS/MS,” BMC Pediatr., vol. 24, no. 1, p. 230, Apr. 2024, doi: 10.1186/s12887-024-04718-x. [32]A. IJzebrink et al., “Informing Parents about Newborn Screening: A European Comparison Study,” Int. J. Neonatal Screen., vol. 7, no. 1, Art. no. 1, Mar. 2021, doi: 10.3390/ijns7010013. [33]G. Joseph, F. Chen, J. Harris-Wai, J. M. Puck, C. Young, and B. A. Koenig, “Parental Views on Expanded Newborn Screening Using Whole-Genome Sequencing,” Pediatrics, vol. 137, no. Supplement_1, pp. S36–S46, Jan. 2016, doi: 10.1542/peds.2015-3731H. [34]B. Y, M. Fa, H. Rz, A. D, and K. Bm, “Reconsidering reproductive benefit through newborn screening: a systematic review of guidelines on preconception, prenatal and newborn screening,” Eur. J. Hum. Genet. EJHG, vol. 18, no. 7, Jul. 2010, doi: 10.1038/ejhg.2010.13. [35]劉美秀 and 曹英, “新生兒聽力缺損之篩檢與照護需求,” 護理雜誌, vol. 63, no. 6, pp. 120–126, Dec. 2016, doi: 10.6224/JN.63.6.120. [36]陳季員 and 鐘育志, “杜顯型肌肉失養症病童之父母面臨的壓力模式,” 護理雜誌, vol. 53, no. 3, pp. 44–51, Jun. 2006, doi: 10.6224/JN.53.3.44. [37]J. Chudleigh et al., “Parents’ Experiences of Receiving the Initial Positive Newborn Screening (NBS) Result for Cystic Fibrosis and Sickle Cell Disease,” J. Genet. Couns., vol. 25, no. 6, pp. 1215–1226, 2016, doi: 10.1007/s10897-016-9959-4. [38]蔡甫昌, 鍾珞筠, 簡穎秀,胡務亮, “大規模人口遺傳疾病篩檢之倫理議題與國家政策,” 台灣醫學, vol. 17, no. 1, pp. 58–69, Jan. 2013, doi: 10.6320/FJM.2013.17(1).10. [39]呂宜珍, 林秀娟, 黃美智, “新生兒篩檢之社會衝擊與倫理考量,” 台灣醫學, vol. 7, no. 5, pp. 774–779, Sep. 2003, doi: 10.6320/FJM.2003.7(5).14. [40]蔡甫昌, 朱怡康,黃天祥, “遺傳檢測與諮詢的倫理議題與執業準則－罹病傾向之遺傳檢測：以BRCA檢驗為例,” J. Med. Educ., vol. 11, no. 1, pp. 69–88, Mar. 2007, doi: 10.6145/jme.200703_11(1).0008. [41]林人傑 and 季瑋珠, “疾病篩檢之倫理議題,” 台灣醫學, vol. 13, no. 2, pp. 170–173, Mar. 2009, doi: 10.6320/FJM.2009.13(2).11. [42]黃美智 and 林秀娟, “Newborn Screening: Should Explicit Parental Consent Be Required?,” Acta Paediatr. Taiwan., vol. 44, no. 3, pp. 126–129, Jun. 2003, doi: 10.7097/APT.200306.0126. [43]"Reconsidering reproductive benefit through newborn screening: a systematic review of guidelines on preconception, prenatal and newborn screening - PubMed.” Accessed: Jul. 26, 2025. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/20197792/ [44]M. Conway, T. T. Vuong, K. Hart, A. Rohrwasser, and K. Eilbeck, “Pain points in parents’ interactions with newborn screening systems: a qualitative study,” BMC Pediatr., vol. 22, no. 1, p. 167, Mar. 2022, doi: 10.1186/s12887-022-03160-1. [45]Y.-H. Chien and W.-L. Hwu, “The modern face of newborn screening,” Pediatr. Neonatol., vol. 64, pp. S22–S29, Feb. 2023, doi: 10.1016/j.pedneo.2022.11.001. [46]蔡甫昌, 楊尚儒, 張至寧Chih-Ning Chang, 胡務亮, 楊智超, “遺傳檢測倫理議題及遺傳諮詢倫理準則,” 台灣醫學, vol. 14, no. 6, pp. 658–671, Nov. 2010, doi: 10.6320/FJM.2010.14(6).09. [47]C. F. Wright, D. R. FitzPatrick, and H. V. Firth, “Paediatric genomics: diagnosing rare disease in children,” Nat. Rev. Genet., vol. 19, no. 5, pp. 253–268, May 2018, doi: 10.1038/nrg.2017.116. [48]“Prevalence of Pathogenic Variants in Cardiomyopathy-Associated Genes in Myocarditis | Circulation: Genomic and Precision Medicine.” Accessed: Jul. 26, 2025. [Online]. Available: https://www.ahajournals.org/doi/10.1161/CIRCGEN.121.003408 [49]F. Boemer et al., “Population-based, first-tier genomic newborn screening in the maternity ward,” Nat. Med., vol. 31, no. 4, pp. 1339–1350, Apr. 2025, doi: 10.1038/s41591-024-03465-x. [50]“Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease | Human Genetics.” Accessed: Jun. 28, 2025. [Online]. Available: https://link.springer.com/article/10.1007/s00439-013-1331-2 [51]S. Jiang, H. Wang, and Y. Gu, “Genome Sequencing for Newborn Screening—An Effective Approach for Tackling Rare Diseases,” JAMA Netw. Open, vol. 6, no. 9, p. e2331141, Sep. 2023, doi: 10.1001/jamanetworkopen.2023.31141. [52]M. C. Nurchis et al., “Whole genome sequencing diagnostic yield for paediatric patients with suspected genetic disorders: systematic review, meta-analysis, and GRADE assessment,” Arch. Public Health Arch. Belg. Sante Publique, vol. 81, no. 1, p. 93, May 2023, doi: 10.1186/s13690-023-01112-4. [53]“(PDF) Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database.” Accessed: Jun. 28, 2025. [Online]. Available: https://www.researchgate.net/publication/335846919_Estimating_cumulative_point_prevalence_of_rare_diseases_analysis_of_the_Orphanet_database [54]J. C. van Campen et al., “Next Generation Sequencing in Newborn Screening in the United Kingdom National Health Service,” Int. J. Neonatal Screen., vol. 5, no. 4, p. 40, Dec. 2019, doi: 10.3390/ijns5040040. [55]“Expanded Newborn Screening Using Genome Sequencing for Early Actionable Conditions | Genetics and Genomics | JAMA | JAMA Network.” Accessed: Jun. 08, 2025. [Online]. Available: https://jamanetwork.com/journals/jama/fullarticle/2825327 [56]O. Ceyhan-Birsoy et al., “Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns: Results from the BabySeq Project,” Am. J. Hum. Genet., vol. 104, no. 1, pp. 76–93, Jan. 2019, doi: 10.1016/j.ajhg.2018.11.016. [57]“Evaluating parental genetic knowledge of hearing loss with and without pre-test genetic counseling in a pediatric otolaryngology clinic - PubMed.” Accessed: Jun. 08, 2025. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/33734538/ [58]R. Patel, B. Friedrich, S. C. Sanderson, H. Ellard, and C. Lewis, “Parental knowledge, attitudes, satisfaction and decisional conflict regarding whole genome sequencing in the Genomic Medicine Service: a multisite survey study in England,” J. Med. Genet., vol. 62, no. 4, pp. 289–297, Mar. 2025, doi: 10.1136/jmg-2024-110458. [59]“Perceived Benefits, Risks, and Utility of Newborn Genomic Sequencing in the BabySeq Project - PubMed.” Accessed: Jun. 08, 2025. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/30600265/ [60]“Participant mothers’ attitudes toward genetic analysis in a birth cohort study | Journal of Human Genetics.” Accessed: Jun. 08, 2025. [Online]. Available: https://www.nature.com/articles/s10038-020-00894-7 [61]H. Eum et al., “Differences in attitudes toward genetic testing among the public, patients, and health-care professionals in Korea,” Eur. J. Hum. Genet. EJHG, vol. 26, no. 10, pp. 1432–1440, Oct. 2018, doi: 10.1038/s41431-018-0191-6. [62]G. E. Hardart and W. K. Chung, “Genetic testing of children for diseases that have onset in adulthood: the limits of family interests,” Pediatrics, vol. 134 Suppl 2, no. Suppl 2, pp. S104-110, Oct. 2014, doi: 10.1542/peds.2014-1394F. [63]B. Armstrong et al., “Parental Attitudes Toward Standard Newborn Screening and Newborn Genomic Sequencing: Findings From the BabySeq Study,” Front. Genet., vol. 13, p. 867371, 2022, doi: 10.3389/fgene.2022.867371. [64]J. C. Sapp et al., “Parental attitudes, values, and beliefs toward the return of results from exome sequencing in children,” Clin. Genet., vol. 85, no. 2, pp. 120–126, Feb. 2014, doi: 10.1111/cge.12254. [65]D. F. Vears, S. Ayres, J. Boyle, J. Mansour, A. J. Newson, and Education, Ethics and Social Issues Committee of the Human Genetics Society of Australasia, “Human Genetics Society of Australasia Position Statement: Predictive and Presymptomatic Genetic Testing in Adults and Children,” Twin Res. Hum. Genet. Off. J. Int. Soc. Twin Stud., vol. 23, no. 3, pp. 184–189, Jun. 2020, doi: 10.1017/thg.2020.51. [66]J. R. Botkin et al., “Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents,” Am. J. Hum. Genet., vol. 97, no. 1, pp. 6–21, Jul. 2015, doi: 10.1016/j.ajhg.2015.05.022. [67]A. A. Parkman et al., “Public awareness of genetic nondiscrimination laws in four states and perceived importance of life insurance protections,” J. Genet. Couns., vol. 24, no. 3, pp. 512–521, Jun. 2015, doi: 10.1007/s10897-014-9771-y. [68]E. M. Bednar et al., “Experiences of Family Communication and Cascade Genetic Testing for Hereditary Cancer in Medically Underserved Populations-A Qualitative Study,” Cancer Prev. Res. Phila. Pa, vol. 17, no. 1, pp. 19–28, Jan. 2024, doi: 10.1158/1940-6207.CAPR-23-0303. [69]R. Dimond, S. Doheny, L. Ballard, and A. Clarke, “Genetic testing and family entanglements,” Soc. Sci. Med. 1982, vol. 298, p. 114857, Apr. 2022, doi: 10.1016/j.socscimed.2022.114857. [70]S. E. Waisbren, C. M. Weipert, R. C. Walsh, C. R. Petty, and R. C. Green, “Psychosocial Factors Influencing Parental Interest in Genomic Sequencing of Newborns,” Pediatrics, vol. 137 Suppl 1, no. Suppl 1, pp. S30-35, Jan. 2016, doi: 10.1542/peds.2015-3731G. [71]S. Pereira et al., “Psychosocial Effect of Newborn Genomic Sequencing on Families in the BabySeq Project: A Randomized Clinical Trial,” JAMA Pediatr., vol. 175, no. 11, pp. 1132–1141, Nov. 2021, doi: 10.1001/jamapediatrics.2021.2829. [72]R. Cheung, S. Jolly, M. Vimal, H. L. Kim, and I. McGonigle, “Who’s afraid of genetic tests?: An assessment of Singapore’s public attitudes and changes in attitudes after taking a genetic test,” BMC Med. Ethics, vol. 23, no. 1, p. 5, Jan. 2022, doi: 10.1186/s12910-022-00744-5. [73]Z. Zhang et al., “Attitudes toward Pursuing Genetic Testing among Parents of Children with Autism Spectrum Disorder in Taiwan: A Qualitative Investigation,” Int. J. Environ. Res. Public. Health, vol. 19, no. 1, p. 118, Dec. 2021, doi: 10.3390/ijerph19010118. [74]I. Mochiki et al., “Psychological characteristics of Japanese patients and their family members receiving genetic counseling: A single-institute exploratory study,” J. Genet. Couns., vol. 32, no. 1, pp. 128–139, Feb. 2023, doi: 10.1002/jgc4.1629. [75]“遺傳諮詢對減緩新生兒篩檢陽性個案家長焦慮程度之成效：以G6PD缺乏症為例__臺灣博碩士論文知識加值系統.” Accessed: Jul. 27, 2025. [Online]. Available: https://ndltd.ncl.edu.tw/cgi-bin/gs32/gsweb.cgi?o=dnclcdr&s=id=%22100NTU05538014%22.&searchmode=basic [76]J. Cohen, Statistical power analysis for the behavioral sciences, 2. ed., Reprint. New York, NY: Psychology Press, 2009. [77]A. Alotaibi et al., “Exploring People’s Knowledge of Genetics and Attitude towards Genetic Testing: A Cross-Sectional Study in a Population with a High Prevalence of Consanguinity,” Healthc. Basel Switz., vol. 10, no. 11, p. 2227, Nov. 2022, doi: 10.3390/healthcare10112227. [78]H. Jaya, S. N. Idayu Matusin, A. Mustapa, M. S. Abdullah, and M. R. W. Haji Abdul Hamid, “Public knowledge of and attitudes toward genetics and genetic testing in Brunei Darussalam,” Front. Genet., vol. 14, p. 1181240, 2023, doi: 10.3389/fgene.2023.1181240. [79]S. B. Haga et al., “Public knowledge of and attitudes toward genetics and genetic testing,” Genet. Test. Mol. Biomark., vol. 17, no. 4, pp. 327–335, Apr. 2013, doi: 10.1089/gtmb.2012.0350. [80]L. Madlensky, A. M. Trepanier, D. Cragun, B. Lerner, K. M. Shannon, and H. Zierhut, “A Rapid Systematic Review of Outcomes Studies in Genetic Counseling,” J. Genet. Couns., vol. 26, no. 3, pp. 361–378, Jun. 2017, doi: 10.1007/s10897-017-0067-x. [81]“Full article: Public concerns about direct-to-consumer DNA test kits: the evidence from survey and social media data.” Accessed: Jun. 08, 2025. [Online]. Available: https://www.tandfonline.com/doi/full/10.1080/14636778.2025.2456259 [82]“Genetic privacy laws and patients’ fear of discrimination by health insurers: the view from genetic counselors - PubMed.” Accessed: Jun. 08, 2025. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/11210377/ [83]H. Etchegary, J. Green, P. Parfrey, C. Street, and D. Pullman, “Community engagement with genetics: public perceptions and expectations about genetics research,” Health Expect. Int. J. Public Particip. Health Care Health Policy, vol. 18, no. 5, pp. 1413–1425, Oct. 2015, doi: 10.1111/hex.12122. [84]“Willingness to participate in genome testing: a survey of public attitudes from Qatar - PubMed.” Accessed: Jun. 08, 2025. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/32724056/ [85]J. Strohmaier et al., “Attitudes toward the right to autonomous decision-making in psychiatric genetic testing: Controversial and context-dependent,” Am. J. Med. Genet. Part B Neuropsychiatr. Genet. Off. Publ. Int. Soc. Psychiatr. Genet., vol. 180, no. 8, pp. 555–565, Dec. 2019, doi: 10.1002/ajmg.b.32724. [86]H. Etchegary, E. Dicks, K. Hodgkinson, D. Pullman, J. Green, and P. Parfey, “Public attitudes about genetic testing in the newborn period,” J. Obstet. Gynecol. Neonatal Nurs. JOGNN, vol. 41, no. 2, pp. 191–200, Mar. 2012, doi: 10.1111/j.1552-6909.2012.01341.x. [87]Genetic Alliance and The New York-Mid-Atlantic Consortium for Genetic and Newborn ScreeningServices, Understanding Genetics: A New York, Mid-Atlantic Guide for Patients and Health Professionals. in Genetic Alliance Monographs and Guides. Washington (DC): Genetic Alliance, 2009. Accessed: Jun. 08, 2025. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK115563/ [88]E. Schnabel-Besson et al., “Parental and child’s psychosocial and financial burden living with an inherited metabolic disease identified by newborn screening,” J. Inherit. Metab. Dis., vol. 48, no. 1, p. e12784, Jan. 2025, doi: 10.1002/jimd.12784. [89]“Survey of patient satisfaction with genetic counseling services in Korea - Choi - 2025 - Journal of Genetic Counseling - Wiley Online Library.” Accessed: Jun. 08, 2025. [Online]. Available: https://onlinelibrary.wiley.com/doi/10.1002/jgc4.1922 [90]C. A. Genetti et al., “Parental interest in genomic sequencing of newborns: enrollment experience from the BabySeq Project,” Genet. Med. Off. J. Am. Coll. Med. Genet., vol. 21, no. 3, pp. 622–630, Mar. 2019, doi: 10.1038/s41436-018-0105-6. [91]E. Crellin, M. Martyn, B. McClaren, and C. Gaff, “What matters to parents? A scoping review of parents’ service experiences and needs regarding genetic testing for rare diseases,” Eur. J. Hum. Genet. EJHG, vol. 31, no. 8, pp. 869–878, Aug. 2023, doi: 10.1038/s41431-023-01376-y. [92]“Psychosocial impact of genetic testing on parents of children with developmental and epileptic encephalopathy - Nevin - 2022 - Developmental Medicine & Child Neurology - Wiley Online Library.” Accessed: Jun. 08, 2025. [Online]. Available: https://onlinelibrary.wiley.com/doi/10.1111/dmcn.14971 | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/100559 | - |
| dc.description.abstract | 背景: 隨著次世代定序技術的發展，全外顯子定序(Whole Exome Sequencing, WES)逐漸被納入臨床應用，成為輔助新生兒疾病診斷的重要工具。新生兒基因定序檢測有助於早期發現可治療的疾病，提供家庭健康相關資訊，但也伴隨不確定性、大量資訊暴露、心理層面影響及基因歧視等問題。因此，本研究旨在探討新生兒父母對WES應用於新生兒臨床篩檢的決策、認知及態度。
方法: 本研究採世代研究(cohort study)設計，以臺大醫院三個月內接受WES檢測之新生兒父母為對象，以線上結構式問卷進行，並於五個不同時間點進行，分別為父母不同意WES檢測當下、遺傳諮詢介入前與後問卷、父母同意WES檢測當下問卷及WES檢測結果釋出後問卷，分別收集其認知行為及態度，並使用比較性統計及描述性統計進行分析 結果:本研究向70位新生兒父母說明新生兒WES檢測同意書內容，23人(32.9%)選擇不同意接受檢測，47位新生兒父母有意願並完成遺傳諮詢前問卷；經遺傳諮詢後，47位父母(61.7%)同意參與檢測並完成47份諮詢後問卷及同意檢測問卷；另回收32份結果釋出後問卷。結果顯示，遺傳諮詢顯著提升父母對檢測的認知(p<0.001)；檢測決策受子女健康評估、自費金額、保險制度與資訊掌握程度影響。多數父母對檢測抱持正向情緒與支持態度，盼納入國家政策並落實書面同意流程。部分父母對費用與保險存有疑慮，且於等待結果期間感到焦慮。大多數父母對遺傳諮詢滿意度高，顯示專業遺傳諮詢為影響檢測決策的重要因素。 結論: 遺傳諮詢對於父母在新生兒基因定序檢測理解扮演關鍵角色。同時，也應重視父母於等待檢測結果期間的焦慮情緒，以及對檢測費用負擔及保險給付條件的擔憂。這些研究發現，在未來新生兒基因檢測廣泛運用前，評估父母接受度與潛在顧慮提供了重要參考。 | zh_TW |
| dc.description.abstract | Background: With the advancement of next-generation sequencing technologies, Whole Exome Sequencing (WES) has been increasingly integrated into clinical practice, serving as an important tool to support the diagnosis of neonatal diseases. Genomic sequencing for newborns enables the early identification of treatable conditions and provides families with valuable health-related information. However, the implementation of such testing also brings challenges, including uncertainty, information overload, psychological impacts, and concerns about genetic discrimination. Therefore, this study aims to investigate parents’ knowledge, behaviors, and attitudes toward the clinical application of WES in newborn screening
Method: This study adopted a cohort study design and targeted parents of newborns who underwent Whole Exome Sequencing (WES) within three months at National Taiwan University Hospital.Data were collected through an online structured questionnaire administered at five different time points: at the time parents declined WES, before genetic counseling, after gentic counseling, at the time parent consented to WES, and after the disclosure of WES result. Parental knowledge, attitudes, and behavioral perspectives were gathered at each stage and analyzed using both comparative and descriptive statistical methods. Results: A total of 70 parents of newborns were provided with information about the content of WES informed consent. Among them, 23 parents (32.9%) declined testing, while 47 expressed interest and completed the pre-counseling questionnaire. After genetic counseling, 47 parents (61.7%) consented to WES and completed the post-counseling and consent questionnaires. Additionally, 32 parents completed the follow-up questionnaire after receiving the results. The findings revealed that genetic counseling significantly enhanced parents’ understanding of WES (p < 0.001). Testing decisions were influenced by factors such as perceived child health status, out-of-pocket cost, insurance concerns, and the level of information comprehension. Most parents held positive emotions and attitudes toward WES, supported its inclusion in national health policy, and emphasized the importance of written informed consent. However, some parents expressed anxiety while awaiting results and had lingering concerns about cost and insurance implications. The overall high satisfaction with genetic counseling highlights its critical role in facilitating informed parental decision-making. Conclusion: Genetic counseling plays a critical role in enhancing parents’ understanding of newborn genomic sequencing. At the same time, it is important to address the anxiety parents may experience while waiting for test results, as well as their concerns regarding the financial burden of testing and potential insurance coverage limitations. These findings offer valuable insights for evaluating parental acceptance and potential concerns prior to the broader implementation of newborn genomic testing in the future. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2025-10-07T16:05:32Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2025-10-07T16:05:32Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 中文摘要 iii 英文摘要 iv 目次 vii 圖次 xi 表次 x 第一章 緒論 1 第一節 研究背景與動機 2 第二章 文獻探討 3 第一節 新生兒篩檢發展制度與挑戰 3 第二節 全外顯子定序發展應用與挑戰 8 第三章 研究架構及研究假設 14 第一節 研究目的 14 第二節 研究架構 15 第三節 研究假設 16 第四章 研究方法 17 第一節 研究設計 17 第二節 研究對象 17 第三節 研究工具 20 第四節 研究倫理 24 第五節 研究收案期間 24 第六節 資料分析 25 第五章 研究結果 26 第一節 基本屬性探討 26 第二節 產前全外顯子定序檢測經驗 28 第三節 全外顯子定序檢測認知之分析 32 第四節 新生兒父母對新生兒全外顯子定序檢測決策因素及感受 42 第五節 新生兒父母於檢測結果釋出後決策、認知及態度分析 55 第六章 討論 65 第一節 基本屬性探討 65 第二節 產前基因定序經驗與資訊來源及檢測態度 65 第三節 遺傳諮詢介入前後父母對全外顯子定序檢測認知 66 第四節 新生兒父母對於新生兒全外顯子定序之決策因素 67 第五節 不同意檢測及同意檢測至結果釋出過程感受及態度 69 第七章 研究限制 72 參考文獻 73 附件 82 | - |
| dc.language.iso | zh_TW | - |
| dc.subject | 全外顯子定序 | zh_TW |
| dc.subject | 父母決策影響因素 | zh_TW |
| dc.subject | 新生兒篩檢 | zh_TW |
| dc.subject | 基因檢測認知 | zh_TW |
| dc.subject | 遺傳諮詢 | zh_TW |
| dc.subject | Genetic Counseling | en |
| dc.subject | Genetic Testing Knowledge | en |
| dc.subject | Whole Exome Sequencing | en |
| dc.subject | Newborn Screening | en |
| dc.subject | Parental Decision-Making Factors | en |
| dc.title | 探討父母對新生兒參與全外顯子定序分析診斷可治療罕見疾病應用之決策、認知及態度 | zh_TW |
| dc.title | Parental Decision-Making, Perceptions, and Attitudes Toward the Use of Whole Exome Sequencing for Diagnosing Treatable Rare Diseases in Newborns | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 113-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 蔡甫昌;李妮鍾;林芯伃 | zh_TW |
| dc.contributor.oralexamcommittee | Daniel Fu-Chang Tsai;Ni-Chung Lee;Shin-Yu Lin | en |
| dc.subject.keyword | 新生兒篩檢,全外顯子定序,基因檢測認知,遺傳諮詢,父母決策影響因素, | zh_TW |
| dc.subject.keyword | Newborn Screening,Whole Exome Sequencing,Genetic Testing Knowledge,Genetic Counseling,Parental Decision-Making Factors, | en |
| dc.relation.page | 96 | - |
| dc.identifier.doi | 10.6342/NTU202503086 | - |
| dc.rights.note | 同意授權(限校園內公開) | - |
| dc.date.accepted | 2025-08-01 | - |
| dc.contributor.author-college | 醫學院 | - |
| dc.contributor.author-dept | 分子醫學研究所 | - |
| dc.date.embargo-lift | 2030-07-30 | - |
| 顯示於系所單位： | 分子醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-113-2.pdf 未授權公開取用 | 1.24 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。